Skip to Content

Rubraca (rucaparib) Disease Interactions

There are 3 disease interactions with Rubraca (rucaparib):

Moderate

Rucaparib (applies to Rubraca) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Based on population pharmacokinetic analyses no dose adjustment is recommended for patients with mild hepatic impairment. Caution should be exercised when using this agent in patients with moderate to severe hepatic impairment as the pharmacokinetics of rucaparib in these patients are unknown.

Moderate

Rucaparib (applies to Rubraca) MDS/AML

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts

Cases of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) have been reported with the use of rucaparib. It is recommended to monitor complete blood count at baseline and monthly thereafter, and as clinically appropriate. Do not start rucaparib until patients have recovered from hematological toxicity caused by previous chemotherapy. It might be necessary to interrupt therapy with rucaparib until blood counts have recovered. If MDS/AML is confirmed, rucaparib should be discontinued.

Moderate

Rucaparib (applies to Rubraca) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

No dose adjustment is recommended for patients with mild to moderate renal impairment. Caution should be exercised when using this agent in patients with severe renal impairment or patients on dialysis as the pharmacokinetics of rucaparib in these patients are unknown.

Rubraca (rucaparib) drug interactions

There are 624 drug interactions with Rubraca (rucaparib)

Rubraca (rucaparib) alcohol/food interactions

There is 1 alcohol/food interaction with Rubraca (rucaparib)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.